US LNG exports surge but will buyers in China turn up?
Investing.com - Globus Medical (NYSE: GMED) reported second quarter EPS of $0.86, $0.10 better than the analyst estimate of $0.76. Revenue for the quarter came in at $745.3M versus the consensus estimate of $739.16M.
Guidance
Globus Medical sees FY 2025 EPS of $3.00-$3.30 versus the analyst consensus of $3.16.
Globus Medical sees FY 2025 revenue of $2.80B-$2.90B versus the analyst consensus of $2.85B.
Globus Medical’s stock price closed at $54.07. It is down -3.14% in the last 3 months and down -26.85% in the last 12 months.
Globus Medical saw 1 positive EPS revisions and 12 negative EPS revisions in the last 90 days. See Globus Medical’s stock price’s past reactions to earnings here.
According to InvestingPro, Globus Medical’s Financial Health score is "great performance".
Check out Globus Medical’s recent earnings performance, and Globus Medical’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar